Wall Street brokerages forecast that XOMA Corp (NASDAQ:XOMA) will announce ($0.49) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for XOMA’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.56). XOMA reported earnings of ($0.16) per share during the same quarter last year, which suggests a negative year over year growth rate of 206.3%. The firm is expected to report its next quarterly earnings results on Wednesday, March 6th.
According to Zacks, analysts expect that XOMA will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.80) to ($1.60). For the next financial year, analysts forecast that the business will post earnings of ($1.31) per share, with EPS estimates ranging from ($2.03) to ($0.80). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow XOMA.
XOMA (NASDAQ:XOMA) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.40). The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%.
Several brokerages have weighed in on XOMA. TheStreet lowered XOMA from a “c-” rating to a “d-” rating in a report on Monday, November 26th. ValuEngine lowered XOMA from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. HC Wainwright set a $36.00 price objective on XOMA and gave the company a “buy” rating in a report on Wednesday, November 7th. Finally, Cowen reissued a “hold” rating on shares of XOMA in a report on Thursday, November 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. XOMA presently has a consensus rating of “Hold” and an average target price of $28.07.
In other XOMA news, insider Value Fund L. P. Biotechnology acquired 36,463 shares of the stock in a transaction that occurred on Thursday, December 13th. The shares were bought at an average price of $14.46 per share, for a total transaction of $527,254.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Value Fund L. P. Biotechnology acquired 25,000 shares of the stock in a transaction that occurred on Monday, December 17th. The stock was acquired at an average price of $14.19 per share, for a total transaction of $354,750.00. The disclosure for this purchase can be found here. Insiders bought 380,177 shares of company stock valued at $5,476,116 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc boosted its position in shares of XOMA by 1.0% in the third quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after acquiring an additional 3,167 shares during the last quarter. Vanguard Group Inc. raised its holdings in XOMA by 1.0% in the third quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock valued at $5,466,000 after buying an additional 3,167 shares during the period. Jefferies Group LLC purchased a new position in XOMA in the third quarter valued at approximately $313,000. GSA Capital Partners LLP raised its holdings in XOMA by 93.9% in the third quarter. GSA Capital Partners LLP now owns 54,915 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 26,600 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in XOMA by 98.7% in the third quarter. Dimensional Fund Advisors LP now owns 54,017 shares of the biotechnology company’s stock valued at $949,000 after buying an additional 26,832 shares during the period. Institutional investors own 42.86% of the company’s stock.
Shares of XOMA stock traded down $0.23 during trading on Tuesday, hitting $13.65. The company’s stock had a trading volume of 56,374 shares, compared to its average volume of 58,733. The firm has a market cap of $114.49 million, a PE ratio of 13.93 and a beta of 2.51. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 19.16. XOMA has a 52 week low of $11.02 and a 52 week high of $34.72.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
See Also: Why are analyst ratings important in trading stocks?
Get a free copy of the Zacks research report on XOMA (XOMA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.